Ancitabine | CAS#31698-14-3 | antineoplastic

MedKoo Cat#: 584903 | Name: Ancitabine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ancitabine is a congener of cyterabine that is metabolized to cytarabine and thereby maintains a more constant antineoplastic action.

Chemical Structure

Ancitabine

CAS#31698-14-3 (free base)

Theoretical Analysis

MedKoo Cat#: 584903

Name: Ancitabine

CAS#: 31698-14-3 (free base)

Chemical Formula: C9H11N3O4

Exact Mass: 225.0750

Molecular Weight: 225.20

Elemental Analysis: C, 48.00; H, 4.92; N, 18.66; O, 28.42

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

31698-14-3 (free base) 10212-25-6 (HCl)

Synonym

Ancitabine

IUPAC/Chemical Name

(2R,3R,3aS,9aR)-2,3,3a,9a-Tetrahydro-3-hydroxy-6-imino-6H-furo(2',3';4,5)oxazolo(3,2-a)pyrimidine-2-methanol

InChi Key

BBDAGFIXKZCXAH-CCXZUQQUSA-N

InChi Code

InChI=1S/C9H11N3O4/c10-5-1-2-12-8-7(16-9(12)11-5)6(14)4(3-13)15-8/h1-2,4,6-8,10,13-14H,3H2/t4-,6-,7+,8-/m1/s1

SMILES Code

OC[C@@H]1[C@@H](O)[C@@](O2)([H])[C@@](N(C2=N3)C=CC3=N)([H])O1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 225.20 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kirsch LE, Notari RE. Pharmacokinetic prodrug modeling: in vitro and in vivo kinetics and mechanisms of ancitabine bioconversion to cytarabine. J Pharm Sci. 1984 Jun;73(6):728-32. PubMed PMID: 6204036. 2: Kirsch LE, Notari RE. Aqueous conversion kinetics and mechanisms of ancitabine, a prodrug of the antileukemic agent cytarabine. J Pharm Sci. 1984 Jul;73(7):896-902. PubMed PMID: 6206222. 3: Webb TR, Mitsuya H, Broder S. 1-(2,3-Anhydro-beta-D-lyxofuranosyl)cytosine derivatives as potential inhibitors of the human immunodeficiency virus. J Med Chem. 1988 Jul;31(7):1475-9. PubMed PMID: 2455053. 4: Nakamura K, Eizuru Y, Kumura K, Minamishima Y. Antiviral effect of antileukemic drugs N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC) and 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine (cyclo-C) against human cytomegalovirus. J Med Virol. 1990 Jun;31(2):141-7. PubMed PMID: 1696958. 5: Valeriote F, Muntz ID, Vietti TJ. Survival of L1210 leukemia cells and normal hematopoietic stem cells following in vivo administration of cyclocytidine. Invest New Drugs. 1985;3(3):255-61. PubMed PMID: 2415478. 6: Liu WG, Chen ZJ, Song JZ, Ma ZX. Effects of 2,2'-O-cyclocytidine and acyclovir on latent herpes simplex virus in trigeminal ganglia of mice. Antimicrob Agents Chemother. 1986 Feb;29(2):278-80. PubMed PMID: 2424367; PubMed Central PMCID: PMC176390. 7: Lee CC, Schrier WH, Nagyvary J. The enzymatic hydrolysis of the phosphate ester bond in some thionucleotides. Biochim Biophys Acta. 1979 Jan 26;561(1):223-31. PubMed PMID: 84687. 8: Meyers PA, Tan CT, Steinherz PG, Redner A. Diaziquone and 2,2'-anhydro-arabinosyl-5-fluorocytosine for the treatment of children with relapsed or refractory acute nonlymphoblastic leukemia. Cancer. 1989 Dec 15;64(12):2416-9. PubMed PMID: 2479459. 9: Cook AF. Fluorinated Pyrimidine nucleosides. 1. Synthesis of a nitrogen analogue of the antitumor agent 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine hydrochloride. J Med Chem. 1977 Mar;20(3):344-8. PubMed PMID: 66315. 10: Sato K, Nomura A, Moffatt JG. Antiviral activities of acyl derivatives of 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosylcytosine in cell culture. Antimicrob Agents Chemother. 1977 Feb;11(2):191-7. PubMed PMID: 66909; PubMed Central PMCID: PMC351951. 11: Hadfield AF, Sartorelli AC. The pharmacology of prodrugs of 5-fluorouracil and 1-beta-D-arabinofuranosylcytosine. Adv Pharmacol Chemother. 1984;20:21-67. Review. PubMed PMID: 6085531. 12: Chen HS, Gross JF. Physiologically based pharmacokinetic models for anticancer drugs. Cancer Chemother Pharmacol. 1979;2(2):85-94. Review. PubMed PMID: 93986. 13: Brugarolas A, Buesa JM, Lacave AJ, Gracia Marco M, Valle Pereda M. Phase I and II clinical study of anhydro-ara-5-fluorocytosine (AAFC) and ICRF-159 combination in adenocarcinoma of digestive origin. Cancer Clin Trials. 1978 Winter;1(4):289-95. PubMed PMID: 93030. 14: Himmelstein KJ, Gross JF. Mathematical model for cyclocytidine pharmacokinetics. J Pharm Sci. 1977 Oct;66(10):1441-4. PubMed PMID: 72816. 15: Hamada A, Kawaguchi T, Nakano M. Clinical pharmacokinetics of cytarabine formulations. Clin Pharmacokinet. 2002;41(10):705-18. Review. PubMed PMID: 12162758. 16: Burgess MA, Bodey GP, Minow RA, Gottlieb JA. Phase I-II evaluation of cyclocytidine. Cancer Treat Rep. 1977 May-Jun;61(3):437-43. PubMed PMID: 68828. 17: Stankovicová M, Rauko P, Bachratá M, Blesová M, Sveda P. In vitro antileukemic activity and chemical transformation of the 5'-chloro-5'-deoxy derivative of cyclocytidine. Neoplasma. 1995;42(5):255-8. PubMed PMID: 8552205. 18: Finklestein JZ, Higgins G, Krivit W, Hammond D. Evaluation of cyclocytidine in children with advanced acute leukemia and solid tumors. Cancer Treat Rep. 1979 Aug;63(8):1331-3. PubMed PMID: 89907. 19: Chou TC, Vidal P, Phillips FS. Comparison of tissue distribution and fate of 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine and 1-beta-D-arabinofuranosyl-5-fluorocytosine in rats. Cancer Treat Rep. 1977 Jul;61(4):617-24. PubMed PMID: 69496. 20: O'Bryan RM, Baker L, Whitecar J, Salmon S, Vaughn C, Hoogstraten B. Cyclocytidine in breast cancer. Cancer Treat Rep. 1978 Mar;62(3):455-6. PubMed PMID: 77189.

View History

PNU-143010

MedKoo CAT#: 526024

CAS#: 1275578-04-5